Cancer Research

#Cancer #FDA #Pancreatic cancer

This week in DDW – oncology focus

DDW Deputy Editor Reece Armstrong takes a look at some of the biggest developments that took place within oncology this week (4 April – 8 April).  Scientists win award for transforming breast cancer treatment  A team of scientists from The Institute of Cancer Research, London,… Read More

#Cancer Research #News

Laboratory research
#Oncology #Pancreatic cancer

Redx collaborates with Garvan on cancer project  

Biotechnology company RedX is collaborating with the Garvan Institute of Medical Research on a project investigating novel therapeutic targets in cancer-associated fibrosis.  The collaboration aims to better understand treatments that could lead to increased patient survival in currently very poorly treated highly fibrotic cancers, such as… Read More

#Cancer Research #News

#Immuno-oncology #Immunotherapy #Immutep

Interview: What an FDA approval means for immunotherapies  

DDW Deputy Editor Reece Armstrong speaks to Professor Frederic Triebel, CSO of Immutep about the approval of Bristol Myers Squibb’s LAG-3 antibody and why it’s causing so much excitement in the sector.    Recently, the Food and Drug Administration (FDA) approved the first combination therapy to block the immune checkpoint receptor protein LAG-3… Read More

#Cancer Research #Exclusive Content #News

#Biomedical research #Cancer #Cannabinoid #Oncology #Plant-based

Can cannabis and mushroom-based products eliminate colon cancer cells?

Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its ‘integrative-colon’ products killed over 90% of colon cancer cells. These products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts. The study… Read More

#Cancer Research #Editor's Choice #News #Trending News

#Cancer research #Immunotherapy #Oncology #Tumours

Immunotherapy challenges and tools for research 

Sonia Marsilio is an Associate Product Manager at Enzo. She explains how research tools enable scientists to accelerate immunotherapy.  The growing, continuously evolving arsenal of cancer immunotherapies has changed the treatment landscape of many tumours. Dominating the space are the CAR T cell therapies, with CD19, BCMA, and CD22… Read More

#Cancer Research #Editor's Choice #News #Opinion

#Cancer #Cancer research #Comment #Healthcare #Public health

Close the care gap: World Cancer Day 2022 

2022's World Cancer Day theme is “Close the Care Gap”1 and is focused on raising awareness of the cancer care equity gap that affects almost everyone, in high as well as low- and middle-income countries, and costs lives. DDW’s Megan Thomas comments on the crisis as well as initiatives that are working to close this… Read More

#Cancer Research #Editor's Choice #Intelligence #News #Opinion #Trends & Analysis

#Immuno-oncology #Immunotherapy #T-Cells

The evolving immuno-oncology landscape 

Dr Ian Walters, Chief Executive Officer and Director of Portage Biotech, shares how to find the path of least resistance through the immuno-oncology landscape.  Our bodies are naturally trained to identify and remove abnormal cells, including those that are cancerous. Under normal circumstances, a person’s immune system detects proteins on the surface of cancer cells and targets them for elimination. The… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Cancer research #Clinical trials #Drug therapy #Therapeutics

Phase I clinical study begins for patients with advanced liver cancer 

The National University Cancer Institute, Singapore (NCIS) and MiNA Therapeutics have dosed the first patients in an investigator-sponsored Phase I study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma (HCC). Atezolizumab and bevacizumab are… Read More

#Cancer Research #News #Trending News

#Clinical trials #Drug development #Drug discovery #Tumours

FDA approves Avacta’s new cancer therapy drug

The US Food and Drug Administration (FDA) has approved Avacta’s Investigational New Drug (IND) application for AVA6000, which will allow the group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States.  What is AVA6000?  AVA6000 is a novel form of… Read More

#Cancer Research #News

Human liver
#Cancer research #Drug development #Immunology / Virology & Vaccines #Liver disease #Research

Does Hepatitis B virus support the survival and growth of liver cancer? 

Researchers at the Francis Crick Institute and Universidade de Santiago de Compostela have identified how the hepatitis B virus (HBV) can support the survival and growth of liver cancer, with this process starting early in tumour development, in some instances up to 20 years before cancer diagnosis.  Context  Around… Read More

#Cancer Research #News

#Cancer research #Drug therapy #Immunotherapy

Agreement to launch breakthrough cancer immunotherapy treatment

Terumo Blood and Cell Technologies and Immunicom have signed a co-commercialisation agreement to help advance a cancer therapy that selectively removes immune inhibitors from a patient’s bloodstream.   What will this achieve?  This potentially enables the patient’s immune system to more effectively attack cancer tumours. In contrast to immunotherapy pharmaceuticals… Read More

#Cancer Research #News #Trending News

#Cancer research #Immunotherapy #Molecular Biology

Inside combination immunotherapies for cancer 

Listen to this article on the DDW Podcast: Combination immunotherapies are one of the most exciting advanced therapy medicinal products (ATMP) being developed, with incredible potential for treating cancer, says Panagiotis Parsonidis, a molecular biologist and lead researcher at RGCC. DDW speaks to him about VAXO-Q-RE developments, a combination immunotherapy that will soon… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Cancer research #Clinical trials #Rare disease #Research

Accelerating research: the path forward for treating rare cancers 

Listen to this article on the DDW Podcast: RareCan is a new company based in the UK. Its aim is to accelerate research into rare cancers. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. Professor Andy Hall, Founding Director and… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion